Dana-Farber Cancer Institute

https://www.dana-farber.org/

 

SGO 2023 Conference Coverage on VuMedi
B

SGO 2023 Phase 1 Trial of Botensilimab + Balstilimab in Patients With Recurrent Platinum Refractory/Resistant Ovarian Cancer

By SGO 2023 Conference Coverage on VuMedi FEATURING Bruno Bockorny
By SGO 2023 Conference Coverage on VuMedi FEATURING Bruno Bockorny
67 views
April 14, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay
Gynecologic
07:23
SGO 2023 Conference Coverage on VuMedi

SGO 2023 Phase 1 Trial of Botensilimab + Balstilimab in Patients Wit…

Feat. B. Bockorny
33:45
Dana-Farber Cancer Institute

Lynch Syndrome and Gynecologic Cancer Risk (and Risk Reduction)

Feat. M. del Carmen